Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Margaret von Mehren, John M. Kane, Mark Agulnik, Marilyn M. Bui, Janai R. Carr, Edwin Choy, Mary Connelly, Sarah Dry, Kristen N. Ganjoo, Ricardo González, Ashley M. Holder, Jade Homsi, Vicki L. Keedy, Ciara M. Kelly, Edward Kim, David A. Liebner, Martin D. McCarter, Sean V. McGarry, Nathan W. Mesko, Christian F. Meyer, Alberto S. Pappo, Amanda Parkes, Ivy A. Petersen, Seth M. Pollack, Matthew M. Poppe, Richard F. Riedel, Scott M. Schuetze, Jacob E. Shabason, Jason K. Sicklick, Matthew B. Spraker, Melissa N. Zimel, Lisa E. Hang, Hema Sundar, Mary Anne Bergman
Abstract
Soft tissue sarcomas (STS) are rare malignancies of mesenchymal cell origin that display a heterogenous mix of clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, blood vessels, and other connective tissues. The evaluation and treatment of patients with STS requires a multidisciplinary team with demonstrated expertise in the management of these tumors. The complete NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Soft Tissue Sarcoma provide recommendations for the diagnosis, evaluation, and treatment of extremity/superficial trunk/head and neck STS, as well as retroperitoneal/intra-abdominal STS, desmoid tumors, and rhabdomyosarcoma. This portion of the NCCN Guidelines discusses general principles for the diagnosis and treatment of retroperitoneal/intra-abdominal STS, outlines treatment recommendations, and reviews the evidence to support the guidelines recommendations.